Oil Prices Rise as U.S.-Iran Talks Fuel Diplomacy Hopes 
NASA, Boeing Discuss Expanding Starliner Missions 
Oil Prices Tumble on U.S.-Iran Diplomacy Hopes, Supply Relief 
OpenAI Urges US-Led Global Standards for Frontier AI 
US, China Extend Trade Truce to Jan. 10 Ahead of Trump-Xi Summit 
Microsoft Stock Upgraded as Stifel Sees Stronger Azure Growth 
Russian Envoy Dmitriev Heads to US for Ukraine Talks 
Volkswagen Shares Slide After 2026 Profit Outlook Cut 
US, Japan and South Korea Back Taiwan Ahead of Trump-Xi Summit 
Dollar Hits Two-Month High as Fed Rate Hike Bets Rise 
Telix to Acquire Germany’s ITM in $1.65 Billion Radiopharma Deal 
Gold Prices Rise as Oil Slump Eases Fed Rate Hike Fears 
Nike Earnings at Risk as UBS Cuts Price Target to $42 
US Northeast Airports Resume Operations After Telecom Outage Disrupts Thousands of Flights 
Oil Prices Surge as U.S.-Iran Diplomacy Hopes Fade 
Paramount-Warner Bros $110 Billion Deal Draws Antitrust Backlash 
Add as a preferred source on Google
COVID-19 vaccines are expensive but a new alternative is coming and this will cut the costs. A division of the Japanese pharma company, Mitsubishi Tanabe Pharma Company, has developed the world’s first plant-based coronavirus vaccine and is looking to launch it soon.
The Medicago biopharmaceutical company that is owned by Mitsubishi Tanabe said that its new COVID-19 vaccine would be cheaper and easier to move compared to the conventional types since this is plant-based. It was also mentioned that Medicago is also backed by the Marlboro producer, Philip Morris International.
According to the Financial Times, the head of Mitsubishi Tanabe Pharma’s vaccine business development, Toshifumi Tada, revealed that Medicago would be applying for approval of its plant-based vaccine in Canada by the end of this year.
With its successful development of the alternative COVID-19 vaccine, the Osaka headquartered pharmaceutical firm is expecting global demand for the product. The company also believes that the demand will remain strong since medical professionals continue to detect new strains of the highly contagious coronavirus.
It was noted that no single plant-based vaccine had been approved yet for use in humans, but supporters of the new technology stated that such a type of vaccine is very appealing since plant leaves grow quickly. This fact alone makes the production process cheaper and faster.
Traditional flu vaccines usually take around eight to 12 months to produce but Medicago’s plant-based alternative will only take up five to eight weeks. Plus, the vaccines do not need to be deep-frozen while being transported, as they can be stored at 2C to 8C temperatures.
“Compared to alternative production systems, our proprietary plant-based manufacturing platform has many advantages, including faster lead time, scalability, and versatility,” Medicago’s senior director of scientific and medical affairs, Nathalie Charland, said via the Nature Research Journal. “The rapid nature of our vaccine and therapeutic protein production unlocks many potential ways in which we can better respond to infectious diseases and public health challenges.”
Meanwhile, Medicago will partner with GlaxoSmithKline for the phase 3 trial for its plant-based vaccine in Canada, U.S., the U.K, Mexico, Brazil, and Argentina. The trial is said to involve 24,000 subjects in all.
